secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0001737287-22-000074
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene initiates Phase 2 ALPHA2 trial of ALLO-501A in r/r LBCL; plans EXPAND trial for ALLO-647
--------------------------------------------------------------------------------

- ALPHA2 trial will enroll ~100 r/r LBCL patients with single 120M CAR+ cell dose; primary endpoint ORR.
- EXPAND trial (~70 patients) randomized to assess ALLO-647 contribution to lymphodepletion regimen.
- FDA cleared manufacturing from CF1 using non-Alloy process; Alloy process being implemented at CF1.
- Company plans to seek FDA approval based on ALPHA2 and EXPAND trials assuming favorable outcomes.
- CD19 program update, including longer-term Phase 1 follow-up with Alloy process, expected end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000074/0001737287-22-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000074/allo-20221006.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer